Please login to the form below

Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

While Bluebird Bio impressed with further strong data on beta thalassemia and sickle cell disease on Friday, the following data saw Novartis and Celgene both unveil longer-term data in DLBCL –

Latest news

More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease

One of the standouts amid all the other blood cancer therapy data released this morning were two updates from Cambridge, Mass-based biotech Bluebird Bio. ... M.D., chief medical officer, Bluebird Bio. Europe’s regulatory the EMA has granted the therapy
J&J moves quickly ahead with trials of myeloma CAR-T

J&J is going up against some well-positioned competitors in the anti-BCMA CAR-T category, notably Celgene and Bluebird Bio with bb2121, Celgene and Juno with and Kite
Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... On the first day of the show, Celgene and Bluebird Bio will be reporting updated data from a phase I trial of
Bluebird bags breakthrough status for CALD gene therapy

Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare neurological disease mainly affecting young males. ... Bluebird’s gene therapy approach could do away with the
Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

EUROPEAN BIOTECH. After bluebird expands deal, Medigene raises 32m. Having expanded its potentially lucrative deal with US biotech bluebird bio, T-cell specialists Medigene has raised an extra 32.3m ... Just last week bluebird bio decided to expand its

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and
Pharma deals in May 2015

Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell
Deal Watch table for June 2014

208. Pregenen/ bluebird bio. Company acquisition. Gene editing technology platform. 156.
Pharma deals during March 2013

344. Bluebird bio/ Celgene Corporation. Option &licence. CAR T-cell therapy for oncology (platform).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal. The US biotech could receive $70m in development milestones for the candidate. ... Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy
Proteostasis Therapeutics strengthens leadership team

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Home based, Editorial Team Leader, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Client Services Director - Med Comms: Great salary and bebefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Editorial Director – Medical Education (MedComms): Neg

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Manager: £40, 000 - £45, 000 benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....